A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial

References

• Bola, J. R., Kao, D. T., & Soydan, H. (2012). Antipsychotic medication for early-episode schizophrenia. Schizophrenia Bulletin, 38, 23–25. doi:10.1093/schbul/sbr167
   PubMed Web of Science ®Google Scholar
• Brewin, C. R., & Bradley, C. (1989). Patient preferences and randomised clinical trials. British Medical Journal, 299, 313–315.10.1136/bmj.299.6694.313
   PubMed Web of Science ®Google Scholar
• Browne, R. H. (1995). On the use of a pilot sample for sample size determination. Statistics in Medicine, 14, 1933–1940.10.1002/(ISSN)1097-0258
   PubMed Web of Science ®Google Scholar
• Crawford, M. J., Robotham, D., Thana, L., Patterson, S., Weaver, T., Barber, R., … Rose, D. (2011). Selecting outcome measures in mental health: The views of service users. Journal of Mental Health, 20, 336–346. doi:10.3109/09638237.2011.577114
   PubMed Web of Science ®Google Scholar
• Francey, S. M., Nelson, B., Thompson, A., Parker, A. G., Kerr, M., Macneil, C., … McGorry, P. D. (2010). Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophrenia Research, 119(1–3), 1–10. doi:10.1016/j.schres.2010.02.1071
   PubMed Web of Science ®Google Scholar
• Freeman, D., & Garety, P. (2003). Connecting neurosis and psychosis: The direct influence of emotion on delusions and hallucinations. Behaviour Research and Therapy, 41, 923–947.10.1016/S0005-7967(02)00104-3
   PubMed Web of Science ®Google Scholar
• Furukawa, T., Levine, S., Tanaka, S., Goldberg, Y., Samara, M., Davis, J., … Leucht, S. (2014). Initial severity of schizophrenia and efficacy of antipsychotics: Participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry, 72, 14–21. doi:10.1001/jamapsychiatry.2014.2127
   Web of Science ®Google Scholar
• Group WHOQOL. (1998). The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social science & medicine, 46, 1569–1585.
   PubMed Web of Science ®Google Scholar
• Haddad, P., & Sharma, S. (2007). Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs, 21, 911–936.10.2165/00023210-200721110-00004
   PubMed Web of Science ®Google Scholar
• Howes, O. (2014). Cognitive therapy: At last an alternative to antipsychotics? The Lancet, 383, 1364–1366.10.1016/S0140-6736(13)62569-6
   PubMed Web of Science ®Google Scholar
• Kay, S., Fiszbein, A., & Opler, L. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Lacro, J. P., Dunn, L. B., & Dolder, C. R. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. The Journal of Clinical Psychiatry, 63, 892–909.10.4088/JCP.v63n1007
   PubMed Web of Science ®Google Scholar
• Law, H., Neil, S., Dunn, G., & Morrison, A. (2014). Psychometric properties of the questionnaire about the process of recovery (QPR). Schizophrenia Research, 156, 184–189.10.1016/j.schres.2014.04.011
   PubMed Web of Science ®Google Scholar
• Law, H., Shryane, N., Bentall, R. P., & Morrison, A. P. (2016). Longitudinal predictors of subjective recovery in psychosis. The British Journal of Psychiatry, 209, 48–53. doi:10.1192/bjp.bp.114.158428
   PubMed Web of Science ®Google Scholar
• Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry, 14, 429–447. doi:10.1038/sj.mp.4002136
   PubMed Web of Science ®Google Scholar
• Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379, 2063–2071.10.1016/S0140-6736(12)60239-6
   PubMed Web of Science ®Google Scholar
• Lincoln, T., Jung, E., Wiesjahn, M., Wendt, H., Bock, T., & Schlier, B. (2016). The impact of negative treatment experiences on persistent refusal of antipsychotics. Comprehensive Psychiatry, 70, 165–173. doi:10.1016/j.comppsych.2016.1007.1009. Epub 2016 Jul 10–30.
   PubMed Web of Science ®Google Scholar
• Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000). Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social funtioning. Acta Psychiatrica Scandinavica, 101, 323–329.
   PubMed Web of Science ®Google Scholar
• Morrison, A. P. (2001). The interpretation of intrusions in psychosis: An integrative cognitive approach to hallucinations and delusions. Behavioural and Cognitive Psychotherapy, 29, 257–276.
   Web of Science ®Google Scholar
• Morrison, A. P. (2017). A manualised treatment protocol to guide delivery of evidence-based cognitive therapy for people with distressing psychosis: Learning from clinical trials. Psychosis Psychological social and integrative approaches. Epub ahead of print.
   Google Scholar
• Morrison, A. P., Hutton, P., Shiers, D., & Turkington, D. (2012). Antipsychotics: Is it time to introduce patient choice? The British Journal of Psychiatry, 201, 83–84. doi:10.1192/bjp.bp.112.112110
   PubMed Web of Science ®Google Scholar
• Morrison, A., Shryane, N., Beck, R., Heffernan, S. H. L., McCusker, M., & Bentall, R. (2013). Psychosocial and neuropsychiatric predictors of subjective recovery from psychosis. Psychiatry Research, 208, 203–209.10.1016/j.psychres.2013.05.008
   PubMed Web of Science ®Google Scholar
• Morrison, A. P., Turkington, D., Pyle, M., Spencer, H., Brabban, A., Dunn, G., … Hutton, P. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomised controlled trial. The Lancet, 383, 1395–1403.10.1016/S0140-6736(13)62246-1
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE). (2014). Psychosis and schizophrenia in adults: Prevention and management. London: Author.
   Google Scholar
• National Institute for Clinical Excellence (NICE) (2016). Psychosis and schizophrenia in children and young people: Recognition and management. London: Author.
   Google Scholar
• Rothman, K. J., & Michels, K. B. (1994). The continuing unethical use of placebo controls. New England Journal of Medicine, 331, 394–398.10.1056/NEJM199408113310611
   PubMed Web of Science ®Google Scholar
• Smith, B., Fowler, D. G., Freeman, D., Bebbington, P., Bashforth, H., Garety, P., … Kuipers, E. (2006). Emotion and psychosis: Links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations. Schizophrenia Research, 86, 181–188.10.1016/j.schres.2006.06.018
   PubMed Web of Science ®Google Scholar
• Tiihonen, J., Lonnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009). 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). The Lancet, 374, 620–627.10.1016/S0140-6736(09)60742-X
   PubMed Web of Science ®Google Scholar
• Torgerson, D., & Sibbald, B. (1998). Understanding controlled trials: What is a patient preference trial? British Medical Journal, 316, 360.10.1136/bmj.316.7128.360
   PubMed Web of Science ®Google Scholar
• Vita, A., De Peri, L., Deste, G., Barlati, S., & Sacchetti, E. (2015). The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: Does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biological Psychiatry, 78, 403–412. doi:10.1016/j.biopsych.2015.02.008
   PubMed Web of Science ®Google Scholar
• Wade, M., Tai, S., Awenat, Y., & Haddock, G. (2016). A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Clinical Psychology Review, 51, 75–95. doi:10.1016/j.cpr.2016.1010.1009. Epub 2016 Oct 28.
   PubMed Web of Science ®Google Scholar
• Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trialrecovery in remitted first-episode psychosisrecovery in remitted first-episode psychosis. JAMA Psychiatry, 70, 913–920, onlinefirst.
   PubMed Web of Science ®Google Scholar
• Yusufi, B. Z., Mukherjee, S., Aitchison, K., Dunn, G., Page, E., & Barnes, T. R. (2005). Inter-rater reliability of the antipsychotic non-neurological side effects scale (ANNSERS). Schizophrenia Bulletin, 31, 574.
   Google Scholar
• Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67, 361–370.10.1111/acp.1983.67.issue-6
   PubMed Web of Science ®Google Scholar